Evidence map›Paper›PMID 41072638›Full record

ReviewBiological psychiatry2026

A Framework for Advancing Mechanistic Neurobehavioral Biomarkers in Psychiatry.

Kangjoo Lee, Jie Lisa Ji, Markus Helmer, John D Murray, John H Krystal, Alan Anticevic

Abstract readReview
In one paragraph

Review in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kangjoo LeeDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. Electronic address: kangjoo.lee@yale.edu.
Jie Lisa JiDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Markus HelmerDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
John D MurrayDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Department of Psychological and Brain Sciences, Dartmouth College, Hanover, New Hampshire.
John H KrystalDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. Electronic address: john.krystal@yale.edu.
Alan AnticevicDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

Funding

ProCAN: Psychosis Risk Outcomes Compound Assessment NetworkU01MH137298 · NIMH · YALE UNIVERSITY · PI CARRIE E BEARDEN, YOUNGSUN T CHO · 2024 to 2026
$48.7M
Translational Technologies CoreP50AA012870 · NIAAA · YALE UNIVERSITY · PI Matthew J Girgenti · 2001 to 2026
$43.7M
Project 5: ComputationalP50MH109429 · NIMH · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · PI STEPHANIE Ruggiano JONES · 2017 to 2026
$25.3M
A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for SchizophreniaU01MH121766 · NIMH · YALE UNIVERSITY · PI KRYSTAL, JOHN H. · 2019 to 2022
$11.8M
NIAAA NIH HHS P50 AA012870NIMH NIH HHS P50 MH109429NIMH NIH HHS U01 MH121766NIMH NIH HHS U01 MH137298
6 · The paper itself

Abstract

Neuropsychiatry has yet to surmount the fundamental challenge of mapping behavioral pathology to its underlying neural pathology. This gap limits the development of treatments for specific circuit pathologies, despite the great potential of neuroimaging measures. We show that the field may be moving toward refining limited statistical frameworks, while clinically translatable solutions could emerge with broader considerations. We posit that the failure to operate within a formalism that defines falsifiable parameters might have hindered progress. Here, we propose a provisional formalism with the intention of bringing elements into focus that seem necessary to advance the development of precision treatments in psychiatry. Specifically, we propose that this formalism should consider 3 defining axes: 1) type of mechanism, 2) severity of mechanism, and 3) time. These 3 axes define a 3-dimensional dynamic mechanism complexity space (MCS). In turn, we posit that at any point in this MCS, there are embedded neurobehavioral subspaces or geometries for neural-to-symptom variation, which themselves are multidimensional and dynamic. This formalism provides for the mapping of the MCS to a neurobehavioral subspace. Furthermore, we articulate how this formalism accommodates integration of spectra from genetics and systems biology (transcriptomics, epigenomics, etc.) to neural mechanisms, symptom variance, and ultimately taxa of mental illness (i.e., categories). Finally, we argue that this formalism creates an opportunity to evaluate different types of treatment development that map onto dynamically evolving mechanisms of illness that are likely a hallmark feature of neuropsychiatric illness.

Indexed as

BiomarkersMental DisordersNeuropsychiatryPsychiatryHumansNeuroimagingBiomarkersBiomarkersComputational psychiatryDisease mechanismDrug developmentNeuroimagingPrecision medicine

Identifiers

PMID41072638
PMCPMC12884387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.